Literature DB >> 17011081

[Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution].

L Haddad1, M Perrinet, D Parent, A Leroy-Cotteau, E Toguyeni, G Condette-Wojtasik, E Hachulla.   

Abstract

BACKGROUND: Intravenous (IV) and subcutaneous (SC) immunoglobulin (Ig) administration is a safe and an efficacious treatment in patients with IgG deficiency. Home administration of IV Ig and SC Ig has recently been approved in France. Most of the patients treated in hospital ask for home treatment. Some patients prefer monthly IV administration, others weekly SC administration.
MATERIAL AND METHODS: We evaluated in details the cost of both of these practices. We currently use electric pumps for both IV and SC administration which are fixed to the patient giving complete freedom and mobility.
RESULTS: For 20 g administrated per 4 week, the total cost of home treatment is 1,518 euro with SC Ig and 1,033 euro with IV Ig. For 40 g administrated per 4 week, the total cost of home treatment is 2,507 euro to 2,729 euro with SC Ig and 2,034 euro with IV Ig. The difference is mainly explained by the cost of renting the electric pumps and by the cost of furniture for SC administration. The choice of home Ig substitution must be given to all patient receiving treatment in hospital.
CONCLUSIONS: Home IV and home SC perfusions are two possible options each different with there own advantages and disadvantages. The cost of each procedure must be known by the medical staff.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011081     DOI: 10.1016/j.revmed.2006.08.005

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  10 in total

1.  Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia.

Authors:  Tanja M Windegger; Son Nghiem; Kim-Huong Nguyen; Yoke L Fung; Paul A Scuffham
Journal:  Blood Transfus       Date:  2019-08-05       Impact factor: 3.443

2.  Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.

Authors:  Eugenia Piscitelli; Marida Massa; Bernardo Maria De Martino; Carmela Simona Serio; Gaspare Guglielmi; Giovanni Colacicco; Francesco Tuccillo; Francesco Habetswallner
Journal:  Eur J Hosp Pharm       Date:  2020-10-29

3.  Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.

Authors:  Clemence Perraudin; Aline Bourdin; Francois Spertini; Jérôme Berger; Olivier Bugnon
Journal:  J Clin Immunol       Date:  2016-05-02       Impact factor: 8.317

Review 4.  Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.

Authors:  Jenny Lingman-Framme; Anders Fasth
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

5.  Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies.

Authors:  J Beauté; P Levy; V Millet; M Debré; Y Dudoit; L Le Mignot; A Tajahmady; C Thomas; F Suarez; I Pellier; O Hermine; N Aladjidi; N Mahlaoui; A Fischer
Journal:  Clin Exp Immunol       Date:  2009-12-16       Impact factor: 4.330

6.  Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.

Authors:  A Martin; L Lavoie; M Goetghebeur; R Schellenberg
Journal:  Transfus Med       Date:  2012-11-20       Impact factor: 2.057

7.  II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.

Authors:  Ekaterini Simões Goudouris; Almerinda Maria do Rego Silva; Aluce Loureiro Ouricuri; Anete Sevciovic Grumach; Antonio Condino-Neto; Beatriz Tavares Costa-Carvalho; Carolina Cardoso Prando; Cristina Maria Kokron; Dewton de Moraes Vasconcelos; Fabíola Scancetti Tavares; Gesmar Rodrigues Silva Segundo; Irma Cecília Barreto; Mayra de Barros Dorna; Myrthes Anna Barros; Wilma Carvalho Neves Forte
Journal:  Einstein (Sao Paulo)       Date:  2017

8.  Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies.

Authors:  Hosein Shabaninejad; Asra Asgharzadeh; Aziz Rezapour; Nima Rezaei
Journal:  Med J Islam Repub Iran       Date:  2017-12-17

9.  Delivery of subcutaneous immunoglobulin by rapid "push" infusion for primary immunodeficiency patients in Manitoba: a retrospective review.

Authors:  Graham Walter; Chrystyna Kalicinsky; Richard Warrington; Marianne Miguel; Jeannette Reyes; Tamar S Rubin
Journal:  Allergy Asthma Clin Immunol       Date:  2020-05-13       Impact factor: 3.406

10.  Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States.

Authors:  Michael C Runken; Joshua M Noone; Christopher M Blanchette; Emily Zacherle; Reuben Howden
Journal:  Am Health Drug Benefits       Date:  2019-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.